BioMarin Pharmaceutical Inc. (BMRN)
Develops enzyme replacement drugs to treat rare genetic and metabolic disorders
$62.07+0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+6.8%
The outlook
BMRN trades at $62.07 with strong analyst backing—25 analysts lean "Buy" on average. The stock sits well above its 50- and 200-day moving averages, roughly three-quarters of the way up its 52-week range. Analysts' average price target sits about 42% above the current price.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 25 analysts
Price trendAbove its 50- & 200-day averages
52-week range75% of the way from its 52-week low to high
Price targetAvg target +42% vs current price
Analyst price target
~12-month · 25 analysts$87.92average target+41.6% vs now
Now $62.07
Low $50.00High $120.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$12.00B
52-wk high
$66.28
52-wk low
$49.26
50-day avg
$56.49
200-day avg
$56.14
Trailing P/E
44.7